STOCK TITAN

X4 Pharmaceuticals: Deep Track reports 6.58% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

X4 Pharmaceuticals, Inc. (XFOR) shares are reported as beneficially owned by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin, who may be considered a control person of Deep Track Capital. As of September 30, 2026, Deep Track Capital and Kroin each reported beneficial ownership of 6,663,821 shares (6.58%), with shared voting and dispositive power. The Master Fund reported 5,737,941 shares (5.66%), and Special Opportunities reported 925,880 shares (0.91%). The reported totals include 2,162,137 pre-funded warrants exercisable for common stock, subject to a 9.99% maximum exercise limitation.

Beneficial ownership — Deep Track Capital, LP and David Kroin 6,663,821 shares (6.58%) each As of September 30, 2026; shared voting and dispositive power
Beneficial ownership — Deep Track Biotechnology Master Fund, Ltd. 5,737,941 shares (5.66%) As of September 30, 2026
Beneficial ownership — Deep Track Special Opportunities Fund, LP 925,880 shares (0.91%) As of September 30, 2026
Pre-funded warrants 2,162,137 warrants Included in reported beneficial ownership; exercisable for common stock
Maximum Percentage 9.99% Exercise limitation on the pre-funded warrants
Common stock outstanding 99,146,743 shares As of July 31, 2026; used in the ownership calculation
Ownership calculation share count 101,308,880 shares Calculation basis described for beneficial ownership
beneficially owned regulatory
"amount beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"Shared Voting Power 6,663,821.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 6,663,821.00"
Pre-Funded Warrants financial
"2,162,137 Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Maximum Percentage regulatory
"the "Maximum Percentage""
joint filing statement regulatory
"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much XFOR stock did Deep Track report beneficially owning?

Deep Track Capital, LP and David Kroin each reported beneficial ownership of 6,663,821 shares (6.58%) as of September 30, 2026. Deep Track Biotechnology Master Fund, Ltd. reported 5,737,941 shares (5.66%), and Deep Track Special Opportunities Fund, LP reported 925,880 shares (0.91%). The totals include pre-funded warrant shares.

What limit applies to the XFOR pre-funded warrants?

The reported amounts include 2,162,137 pre-funded warrants exercisable for common stock, subject to a 9.99% Maximum Percentage exercise limitation. X4 Pharmaceuticals shall not effect an exercise to the extent the holder would beneficially own more than 9.99% of common stock outstanding immediately after the exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





98420X202

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:11/16/2026
Deep Track Biotechnology Master Fund, Ltd.
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:11/16/2026
David Kroin
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:11/16/2026
Deep Track Special Opportunities Fund, LP.
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP
Date:11/16/2026
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of September 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 101,308,880 shares, calculated using 99,146,743 Common Stock outstanding as of July 31, 2026, according to the 10-Q filed with the SEC on August 6, 2026 and 2,162,137 Pre-Funded Warrants that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 2,162,137 Pre-Funded Warrants exercisable to common stock, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Pre-Funded Warrants to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. Deep Track Capital LP and David Kroin may be deemed to be considered beneficial owners of a combined 4,501,684 Common Stock, 2,162,137 Pre-Funded Warrants subject to the Maximum Percentage exercise limitation. Deep Track Biotechnology Master Fund Ltd. is the beneficial owner of 3,575,804 Common Stock, 2,162,137 Pre-Funded Warrants subject to the Maximum Percentage exercise limitation. Deep Track Special Opportunities Fund LP is the beneficial owner of 925,880 Common Stock. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Special Opportunities Fund, LP. By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP

Keep reading